Alternative Data for IQVIA
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2,000 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,135,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 165 | Sign up | Sign up | Sign up |
| Facebook Followers | 70,396 | Sign up | Sign up | Sign up |
| Instagram Followers | 24,914 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,175 | Sign up | Sign up | Sign up |
| X Followers | 17,574 | Sign up | Sign up | Sign up |
| X Mentions | 3 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 65 | Sign up | Sign up | Sign up |
| Linkedin Employees | 80,907 | Sign up | Sign up | Sign up |
About IQVIA
North Carolina-based IQVIA Holdings, Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
| Price | $166.94 |
| Target Price | Sign up |
| Volume | 4,270,000 |
| Market Cap | $28.8B |
| Year Range | $152.32 - $244.29 |
| Dividend Yield | 0% |
| PE Ratio | 21.56 |
| Analyst Rating | 85% buy |
| Industry | Biotechnology |
In the news
 |
Earnings growth of 3.6% over 3 years hasn't been enough to translate into positive returns for IQVIA Holdings (NYSE:IQV) shareholdersFebruary 11 - Yahoo |
|
The Top 5 Analyst Questions From IQVIA’s Q4 Earnings CallFebruary 11 - Yahoo |
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitorsFebruary 11 - MarketWatch |
|
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitorsFebruary 10 - MarketWatch |
|
|
IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related ConditionsFebruary 9 - Yahoo |
IQVIA Partners With Duke Clinical Research Institute To Enhance Conduct Of Clinical Research In Obesity, Cardiometabolic StudiesFebruary 9 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 4.1B | 2.73B | 1.37B | 331M | 883M | 3.000 |
| Q2 '25 | 4.02B | 2.69B | 1.32B | 266M | 781M | 1.540 |
| Q1 '25 | 3.83B | 2.53B | 1.3B | 249M | 753M | 2.700 |
| Q4 '24 | 3.96B | 2.58B | 1.38B | 437M | 1.02B | 2.420 |
| Q3 '24 | 3.9B | 2.52B | 1.38B | 285M | 797M | 1.550 |
Insider Transactions View All
| BOUSBIB ARI filed to sell 820,599 shares at $222.4. December 19 '25 |
| BOUSBIB ARI filed to sell 883,955 shares at $217.6. October 31 '25 |
| BOUSBIB ARI filed to sell 828,198 shares at $222. October 31 '25 |
| BOUSBIB ARI filed to sell 858,299 shares at $220.1. October 31 '25 |
| BOUSBIB ARI filed to sell 876,640 shares at $218.3. October 31 '25 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rob Bresnahan |
Jun 2, 25 | Sell | $1K - $15K |
| Rob Bresnahan |
May 8, 25 | Buy | $15K - $50K |
| Rob Bresnahan |
Mar 28, 25 | Sell | $1K - $15K |
Read more about IQVIA (IQV) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - IQVIA
The Market Cap of IQVIA is $28.8B.
As of today, IQVIA's PE (Price to Earnings) ratio is 21.56.
Currently, the price of one share of IQVIA stock is $166.94.
The IQV stock price chart above provides a comprehensive visual representation of IQVIA's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling IQVIA shares. Our platform offers an up-to-date IQV stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, IQVIA (IQV) does not offer dividends to its shareholders. Investors interested in IQVIA should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of IQVIA are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
